Aligos Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Aligos Therapeutics Inc ALGS.OQ reported a quarterly adjusted loss of $2.11​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-5.50. The mean expectation of three analysts for the quarter was for a loss of $2.80 per share. Wall Street expected results to range from $-3.57 to $-2.37 per share.

• Revenue fell 68.5% to $311.00 thousand from a year ago; analysts expected $333.33 thousand.

• Aligos Therapeutics Inc's reported EPS for the quarter was a loss of $2.11​.

• The company reported a quarterly loss of $18.41 million.

• Aligos Therapeutics Inc shares had fallen by 38.8% this quarter and lost 87.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Aligos Therapeutics Inc is $70.00

This summary was machine generated from LSEG data May 6 at 01:33 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)